ROCKVILLE, Md., Feb. 6, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that President and CEO Richard Garr will present at the 16 th Annual BIO CEO & Investor Conference 2014 in New York City on Tuesday, February 11, at 3:00 p.m. EST. Garr will present clinical updates on the company's 2014 NSI-566 cell therapy trials program, including ongoing ALS Phase II; ALS Phase II in Mexico City; FDA-approved chronic spinal cord injury Phase I; acute spinal cord injury Phase I in Seoul; and ischemic stroke Phase I/II, which commenced in December 2013 in Beijing.
The BIO CEO webcast will be available in real-time at http://www.veracast.com/webcasts/bio/ceoinvestor2014/49237299345.cfm and, again, beginning one hour after the conclusion of the live event, and archived for nine months. The webcast link will also be posted on the Investor Center home page on Neuralstem's website: www.neuralstem.com. For more information on the BIO CEO & Investor Conference 2014, see: http://www.bio.org/events/conferences/bio-ceo-investor-conference .
Neuralstem's President and CEO Richard Garr is also scheduled to present at the 8 th Annual BIO-Europe Spring Conference 2014, held March 10-13, in Turin, Italy. For more information, see: http://www.ebdgroup.com/bes/index.php .About Neuralstem Neuralstem's patented technology enables the production of neural stem cells of the brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glial cells. Neuralstem's NSI-566 spinal cord-derived stem cell therapy is in Phase II clinical trials for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease. Neuralstem has been awarded orphan status designation by the FDA for its ALS cell therapy. In addition to ALS, the Company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury and ischemic stroke. The Company has received FDA approval to commence a Phase I safety trial in chronic spinal cord injury.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV